Prescription GLP-1 treatments are supported by large clinical trials , which is how their effectiveness and side effects are understood
10.3389/fmolb.2022.981963 Summary Keywords ADPKD (autosomal dominant polycystic kidney disease), tolvaptan, metabolic reprograming, therapeutic approaches, metabolism & obesity, GLP-1, glucagon Citation Bakaj I and Pocai A (2023) Metabolism-based approaches for autosomal dominant polycystic kidney disease
If the COVID-19 vaccines were the most significant FDA approvals of the 2020s so far, GLP-1 agonists to treat obesity are a strong runner up
Intermountain Healthcare
No approved therapeutic claims
The study was conducted over the series of many months, and data was analyzed by self-control comparing the participants score on the hangover symptom scale when using NAC compared to placebo